(Q37836669)

24 August 2017

title

The use of zoledronic acid in pediatric cancer patients (English)

1 reference

24 August 2017

1 reference

Keith J August

1

1 reference

24 August 2017

Amanda Dalton

2

1 reference

24 August 2017

Howard M Katzenstein

3

1 reference

24 August 2017

Bradley George

4

1 reference

24 August 2017

Thomas A Olson

5

1 reference

24 August 2017

Karen Wasilewski-Masker

6

1 reference

24 August 2017

Louis B Rapkin

7

1 reference

24 August 2017

language of work or name

1 reference

23 December 2010

1 reference

24 August 2017

published in

Pediatric Blood & Cancer

1 reference

24 August 2017

volume

56

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

610-614

1 reference

Bisphosphonates: mode of action and pharmacology

24 August 2017

cites work

1 reference

Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion

21 January 2018

1 reference

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

21 January 2018

1 reference

Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence

21 January 2018

1 reference

Recommendations for zoledronic acid treatment of patients with bone metastases

21 January 2018

1 reference

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

21 January 2018

1 reference

Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines

21 January 2018

1 reference

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

21 January 2018

1 reference

Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation

21 January 2018

1 reference

The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.

21 January 2018

1 reference

Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.

21 January 2018

1 reference

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

21 January 2018

1 reference

Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy

21 January 2018

1 reference

Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta

21 January 2018

1 reference

Use of bisphosphonate therapy for osteoporosis in childhood and adolescence

21 January 2018

1 reference

Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis

21 January 2018

1 reference

Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia

21 January 2018

1 reference

Zolendronate in osteogenesis imperfecta

21 January 2018

1 reference

Short-term safety assessment in the use of intravenous zoledronic acid in children

21 January 2018

1 reference

Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis.

21 January 2018

1 reference

Efficacy of zoledronate against neuroblastoma

21 January 2018

1 reference

In vitro toxicity of bisphosphonates on human neuroblastoma cell lines

21 January 2018

1 reference

Zoledronic acid inhibits osteosarcoma growth in an orthotopic model

21 January 2018

1 reference

Anticancer effects of zoledronic acid against human osteosarcoma cells.

21 January 2018

1 reference

Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma

21 January 2018

1 reference

Management of the adverse effects associated with intravenous bisphosphonates

21 January 2018

1 reference

Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease

21 January 2018

1 reference

Bisphosphonates in children with hypercalciuria and reduced bone mineral density

21 January 2018

1 reference

Bisphosphonates for treatment and prevention of bone metastases

21 January 2018

1 reference

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

21 January 2018

1 reference

Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid

21 January 2018

1 reference

Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

21 January 2018

1 reference

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

21 January 2018

1 reference

A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma

21 January 2018

1 reference

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PBC.22681

1 reference

24 August 2017

1 reference